Abhinav Bassi
Overview
Explore the profile of Abhinav Bassi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
383
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Humphrey T, Qian W, Chen-Xu M, Dowling F, Gatley K, Adhikari R, et al.
BMC Infect Dis
. 2025 Feb;
25(1):204.
PMID: 39934669
Purpose: Despite vaccination, many patients remain vulnerable to COVID-19 infection and poorer outcomes, because of underlying health conditions resulting in sub-optimal vaccine responses. This study aims to demonstrate whether intranasal...
2.
Gupta L, Bassi A, Vijayaraghavan B, Bains L, Saxena K, Hammond N, et al.
Cureus
. 2024 Nov;
16(10):e71267.
PMID: 39525248
Background: During the COVID-19 pandemic, there were reports of a shortage of ventilators and oxygen supply, particularly in resource-limited settings. We report the preliminary evaluation of a non-invasive positive end-expiratory...
3.
OHara D, Bassi A, Wilcox A, Jha V, Rathore V, DCruz S, et al.
BMJ Open
. 2024 Oct;
14(10):e081790.
PMID: 39438096
Objective: To determine whether a chemokine receptor type 2 antagonist, DMX-200 (repagermanium), in combination with an angiotensin receptor blocker, candesartan, improves clinical outcomes in people with COVID-19. Design: Prospective, multicentre,...
4.
Thankachen S, Devasenapathy N, Bassi A, Ghosh A, Arfin S, Gummidi B, et al.
Trials
. 2024 Jun;
25(1):378.
PMID: 38863076
Background: There is no known effective pharmacological therapy for long COVID, which is characterized by wide-ranging, multisystemic, fluctuating, or relapsing symptoms in a large proportion of survivors of acute COVID....
5.
Jardine M, Kotwal S, Bassi A, Hockham C, Jones M, Wilcox A, et al.
BMJ
. 2022 Nov;
379:e072175.
PMID: 36384746
Objective: To determine whether disrupting the renin angiotensin system with angiotensin receptor blockers will improve clinical outcomes in people with covid-19. Design: CLARITY was a pragmatic, adaptive, multicentre, phase 3,...
6.
Vijayaraghavan B, Jha V, Rajbhandari D, Myatra S, Ghosh A, Bhattacharya A, et al.
BMJ Open
. 2022 Jun;
12(6):e059540.
PMID: 35649613
Objectives: To determine whether hydroxychloroquine when used with personal protective equipment reduces the proportion of laboratory-confirmed COVID-19 among healthcare workers in comparison to the use of personal protective equipment alone....
7.
Granholm A, Kjaer M, Munch M, Myatra S, Vijayaraghavan B, Cronhjort M, et al.
Intensive Care Med
. 2022 Apr;
48(5):580-589.
PMID: 35359168
Purpose: We assessed long-term outcomes of dexamethasone 12 mg versus 6 mg given daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia. Methods:...
8.
Bassi A, Arfin S, Joshi R, Bathla N, Hammond N, Rajbhandari D, et al.
Lancet Glob Health
. 2021 Dec;
10(3):e317-e319.
PMID: 34953516
No abstract available.
9.
Granholm A, Munch M, Myatra S, Vijayaraghavan B, Cronhjort M, Wahlin R, et al.
Intensive Care Med
. 2021 Nov;
48(1):45-55.
PMID: 34757439
Purpose: We compared dexamethasone 12 versus 6 mg daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia in the international, randomised, blinded COVID...
10.
Munch M, Myatra S, Vijayaraghavan B, Saseedharan S, Benfield T, R Wahlin R, et al.
JAMA
. 2021 Oct;
326(18):1807-1817.
PMID: 34673895
Importance: A daily dose with 6 mg of dexamethasone is recommended for up to 10 days in patients with severe and critical COVID-19, but a higher dose may benefit those...